Original Source: Pharmaceutical Market

Buy Now: Market Research

Dallas, TX: ReportsandReports announce it will carry Benchmarking the Pharmaceutical Market by Drug Delivery to 2014 Market Research Report in its Store.

Drug delivery can play an important role at all stages of a drug’s lifecycle and has become an ever present feature in the business model of the leading pharmaceutical companies. Using the PharmaVitae Explorer database, the report provides an in depth sales analysis of the specific routes of administration driving the pharmaceutical market out to 2014

The oral and injectable segments are the dominant routes of administration in the prescription pharmaceutical market, accounting for more than 80% of combined sales in 2008.

Injectables will see the biggest increase in annual sales at $49 billion over 200814. In contrast, oral drugs will collectively decline by $10.9 billion over the same period.

Slow-growth therapy areas are generally entrenched in oral medications. This dynamic is mirrored by the fast-growth therapy areas, where novel injectable drugs will primarily drive growth.

PharmaVitae Explorer database 3

Chapter structure 4

Data sourcing 4

Key findings

Drug delivery overview 6

Prescription pharmaceutical market by delivery mechanism, 2002–14 12

Key findings

Introduction to drug delivery 28

Key findings

Segmentation of the drug delivery market 35

Segmentation by mode of delivery 37

Segmentation by technology type 45

Merging technology with commercial opportunity 48

Key findings

A delivery-focused sales analysis of the leading prescription pharmaceutical companies 51

Prescription pharmaceutical market by delivery mechanism 53

Drug delivery analysis of the leading pharmaceutical players by company 67

Drug delivery analysis of the leading pharmaceutical players by company 74

References

Abbreviations 80

Exchange rates 81

About Datamonitor 82

Datamonitor consulting 82

Disclaimer 84

Browse complete Report on: Benchmarking the Pharmaceutical Market by Drug Delivery to 2014

Browse all Healthcare Market Research Reports

Browse all Newly Published Market Research Reports

Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004

Website: http://www.reportsandreports.com/

Blog: http://reportsnreports.wordpress.com/

Blog: http://reportsandreports.blogspot.com/

Browse complete 2010-2014 Deep Research Report on China Wind Turbine Blade Industry Report

Browse all Packaged Facts Market Research Reports

2010-2014 Deep Research Report on China Wind Turbine Blade Industry focus on China Wind Blade Industry, introduced China Wind turbine blade industry current status and coming years development trend forecast.this report firstly introduced wind turbine blade manufacturing processes and technology and also introduced technology applications and related processes raw materials and equipments source. Then introduced China wind turbine blade capacity production supply demand and 2010-2014 forecast. and then, introduced China 18 wind turbine companies all kinds of blades(750KW 850KW 1MW 1.25MW 1.5MW 2.0MW 2.5MW 3.0MW etc) capacity production Cost Price Profit Profit Margin downstream wind turbine customers(such as Sinovel Gold Wind DEC etc) and capacity expansion plan, also introduced China all blade companies capacity market share production market share, total wind turbine blade supply from 2009-2014 and China wind turbine blade demand from 2009-2014, and wind turbine blade shortage from 2009-2014,wind turbine cost price production value profit margin from 2009-2014 and wind turbine blade supply relationship with wind turbine companies.what is more, most of related data or information were list by wind turbine blade Specification(750KW 850KW 1MW 1.25MW 1.5MW 2.0MW 2.5MW 3.0MW etc). Finally, the report conduct a comprehensive summary of China Wind Turbine Blade industry, including the past present and forecast the future, we also make a feasibility analysis of 500 sets/year 1.5MW Wind Turbine blade project,we carry out an accurate calculation on investment cost, revenue, profitability, payback period. In a word, it was a depth research report on china Wind Turbine Blade industry chain. And thanks to the China Wind Turbine Blade marketing or technology experts help and support during QYResearch Wind Energy team survey and interviews.

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004

Browse complete Future of Plant Growth Regulators in China 2010-2014 Report

Browse all CCM International Market Research Reports

China’s plant growth regulator industry has seen remarkable progress in recent years, showing show attractive market potential in the future. Total output and output value of plant growth regulators reached 29,962 tonnes and USD256 million respectively in 2009. About 60% outuput was exported in 2009, the ramaining 40% output about 11,776 tonnes was consumed in domestic.

This report aims to provide comprehensive understanding about Chinese plant growth regulator industry and to find out investment risk and business opportunities in this field. Following aspects of plant growth regulator industry are covered in this report.

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004

Browse complete South African Pharmaceutical Market Outlook to 2014: Policy environment, market structure, competitive landscape, growth opportunities Report

Browse all Business Insights Market Research Reports

The South African pharmaceutical market was worth over $2bn in 2008. Nearly 75% of pharmaceutical demand in South Africa is met by imports and hence the market value is heavily dependent on currency fluctuations. During 2007-08, the market posted double-digit growth in local currency terms, while declining in US dollar value. Overall sales from the market is expected to pass $3bn in 2012. Factors contributing to growth include the upcoming overhaul of the pharmaceutical regulatory system and healthcare delivery mechanism as well as growth of certain therapy areas in the country.

In general, the replacement of the Medicines Control Council (MCC) with the South African Health Products Regulatory Authority (SAHPRA) and the establishment of a universal healthcare scheme namely the National Health Insurance (NHI) will benefit all companies similarly. The arrival of SAHPRA is being viewed positively by industry organizations as this will lead to expediting drug approvals that translates to faster commercialization and speedier returns on investments. The establishment of a universal healthcare buyer and provider promises increased drug delivery and utilization in the country. However, ramifications in pharmaceutical pricing will threaten margins as bargaining power of a central financier will be significantly higher than the existing fragmented consumer base.

• Socioeconomic, demographic and epidemiological analysis – Assessment of socioeconomic and demographic features of South Africa. The report also evaluates healthcare delivery parameters in the region.
• Regulatory policy analysis – Insights into the government policy environment relating to pharmaceutical regulation, pricing and reimbursement, and its impact on the industry.
• Sales distribution analysis – Comprehensive analysis of sales distribution in the South African market based on therapeutic classes, brands and companies. The report also analyses the distribution of sales between local players and MNCs operating in the country.
• Market competition/fragmentation analysis – Analysis of market concentration/fragmentation in line with general anti-trust protocols.
• Key events, issues and trends in the South African pharmaceutical market – Impact of key events, issues and trends on the market and Business Insights recommendations to identify resultant opportunities and threats.

• Quantify disease burden of various communicable and non-communicable pathophysiologic disorders
• Gain a comprehensive understanding of the regulatory, pricing and reimbursement policies and their impact on the industry
• Discover therapy areas with the greatest franchise growth potential and understand the growth drivers.
• Measure the impact of key events, issues and trends in the regulatory landscape, healthcare delivery and therapy areas and be advised with ideas to navigate through the changing environment.
• Forecast sales of all therapy areas through 2014.

• Replacement of the MCC by SAHPRA: 2010 will witness the landmark replacement of the MCC with a new authority called the SAHPRA. The SAHPRA is designed to overcome much of the downsides of the MCC. Expedited product approvals and consequent rise in sales is expected.
• The CD4 count criteria for ARV raised from <200 to <350 cells/mm3: The recently announced ‘Comprehensive Plan for the Treatment, Management and Care of HIV and AIDS’ underlines the necessity for extending ARVs to HIV/AIDS patients with <350 cells/mm3. With the implementation of this milestone policy change the South African government intends to ensure ARV availability to over 80% of affected individuals and reduce rate of new infections by 50% by 2011. This presents significant opportunity for ARV manufacturers as volume requirements will nearly quadruple during this period.
• Proposed establishment of the National Health Insurance (NHI): The establishment of a universal health insurance scheme brings to notice opportunities as well threats to the pharmaceutical industry. Opportunities include increased drug utilization and better reimbursement options for expensive medications, while threats include increased pricing pressure.
• GSK grants license of its pharmaceutical business in South Africa to Aspen: GSK granted Aspen licenses to its business in South Africa in return for a stake in the latter. The deal will significantly expand Aspen’s products portfolio, while forming a part of GSK’s global strategy to expand its presence in emerging markets.

• The South African pharmaceutical market was worth more than $2bn in 2008. The market depends heavily on imports and hence earnings are quite volatile due to currency fluctuations. Although the market posted a decline in USD terms, growth in local currency was in double digits.
• The proposed establishment of a universal healthcare system poses certain threats to the pharmaceutical industry such as the greater bargaining power of a central funding body, more price regulations and rise in generic utilization.
• South Africa is awaiting a landmark regulatory overhaul in 2010. The replacement of its central regulator, the Medicines Control Council, with a newly designed South African Health Products Regulatory Authority is set to boost pharmaceutical growth.
• Anti-infectives formed the largest therapy area in the country, while antineoplastics formed the fastest growing. The South African ARV tender is the largest of the kind globally and accounts for approximately 10% of the overall market. Recent budget announcements indicate that the value and volume of the tender is set to rise dramatically in the coming years. Positioning with respect to share in the ARV tender significantly affects competitive landscape.

• What will be the major growth indications/disorders and the accompanying growth drivers in the South African market over 2008–14?
• How do government polices on pharmaceutical regulation, pricing and reimbursement impact the industry?
• What are the implications of the replacement of the MCC with SAHPRA?
• What factors will affect approval and distribution of the third ARV tender due in May-June 2010?
• How will the establishment of the National Health Insurance influence the market?
• What are the current market trends across major therapy segments in South Africa?

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004

Browse complete The South Korean Pharmaceutical Market Outlook to 2014: Healthcare regulation and reforms, disease burden and market dynamics Report

Browse all Business Insights Market Research Reports

South Korea has moved from being a developing pharmaceutical market to a fully fledged developed market in the past ten years. The Ministry of Health and Welfare is the nodal agency for protecting public health in South Korea. The country’s public health status has improved with respect to infant mortality and life expectancy. This has been fueled by rising income levels and resultant improved living conditions and an improved healthcare system.

Healthcare in South Korea is provided principally by the private sector: 93% of medical institutions are privately held and 90% of specialist doctors work for the private sector. In terms of healthcare expenditure, public healthcare spending has grown at an annual rate of 10.1% on a per capita basis since 1981, which is far above the OECD average of 3.6%.

The South Korean drug approval system is a long-winded process and innovator drug companies are required to obtain several certificates and licenses and have to appear for numerous face-to-face meetings with regulatory officials, during and post the approval process. Foreign manufacturers also find the shipment of imported drugs for testing to be a time-consuming and expensive process.

National Health Insurance (NHI) or the Medical Aid Program (governed by the Ministry of Health and Welfare) are the key bodies which provide healthcare benefits to all citizens of South Korea. The NHI is again financed through contributions from employers and the insured, besides government subsidies. The contribution from an insured employee is determined by the standard monthly wage (half of the contribution or 50% is paid by the employee and the other half by the employer).

• Macroeconomic environment in South Korea includes economic snapshot, population profile and demographic trends, disease burden and epidemiology
• South Korean healthcare system and regulation involving key trends & events, detailed overview of the healthcare system, healthcare financing, recent healthcare reforms, drugs approval process, intellectual property laws and medical tourism
• Overview of the South Korean pharmaceutical market covering comparative dynamics of emerging & major pharmaceutical market, key recent events and trends, therapeutic category analysis, leading product dynamics, generic drug market and the overall market forecast through 2014
• Forecasts and analysis of the leading products in the South Korean pharmaceutical market over the period 2008–14 spread across major therapeutic indications and classes of treatments

• Develop insights for the South Korean pharmaceutical market, pricing & regulation, healthcare system and detailed epidemiological status of the common indications/risk factors in the country
• Quickly understand how recent events are affecting the performance of major products, and how the marketers are confronting competitive challenges and a range of strategic responses that are taking shape n the South Korean market
• Gain up-to-date competitive intelligence across a wide-range of marketed products, R&D pipeline, market share data, sales forecast and competitive landscape for the major players in the South Korean pharmaceutical market
• Understand which indications have the greatest potential to provide franchise growth, and how pharmaceutical companies are attempting to capitalize these opportunities in South Korea

• Biotech drugs focused in the economic plan: As per a plan finalized by the South Korean government in early 2009 to facilitate mid-term economic growth, R&D is to be supported in 17 key industries that include biologics. According to this plan, which has been agreed upon by a presidential policy council and the national science and technology council, a total of $4.66bn would be invested over the next 4 years on different fields including general healthcare. The over all aim of this plan is to drive economic growth.
• OTC medicines set to grow: OTC medicines have been a growing segment in South Korea due to the regional trend of self-prescription. Besides, product branding is also an important factor with studies showing that 35% of the consumers stick to the brand of medicine that they always buy. Over the medium term, factors that are likely to sustain growth in the sector include retail sector liberalization which is likely to expose people to products for self-medication more frequently. Switch from prescription to OTC is likely to trigger the introduction of newer pharmaceuticals in product portfolios.
• Glivec battling pricing issues in South Korea: Novartis has been battling legal action over the pricing of Glivec in South Korea. In January 2010, Seoul Administrative Court dismissed a petition over Glivec price reduction that was filed by a civic group. The court ruled that imposing such a reduction would disrupt the regular regulatory procedures of drug pricing, followed by the government review process. South Korea patients already had access to Glivec through the government driven insurance schemes. Besides, Novartis has been providing for co-payments that allow patients to receive the drug for free without any out-of-pocket expense.

• South Korean pharmaceutical market was valued at around $9bn in 2008, recording a Y-o-Y decline of 4.5%. However, during 2004–08 period, the country recorded strong growth with a CAGR of around 14%. IMS Health recently classified South Korean pharmaceutical market as developed but the country’s pharmaceutical market growth has been trailing many of the emerging markets such as China, Russia and Brazil.
• South Korean pharmaceutical market is yet to reach a level of growth like that of the high growth emerging markets, a scenario that may change considering the ongoing reform of pricing system for prescription pharmaceuticals.
• Alimentary tract and metabolism remained the leading therapeutic area in South Korea with a market share of 20%. However, most of the market leading therapy areas in the country recorded a decline over the 2007–08 period primarily due to prevailing unfavorable economic conditions and currency fluctuations.
• Top 10 drugs of the South Korean pharmaceutical market contributed only 6.4% of the total sales in 2008, with ‘others’ accounting for a substantial share of 93.6%. BMS/Sanofi-aventis’ Plavix and Pfizer’s Lipitor remained the best -selling drugs in 2008.
• The competitive landscape of the South Korean pharmaceutical market has a fair representation from both domestic and multinational players. The top ten players together captured 35.2% of the total pharmaceutical market in 2008. Domestic pharmaceutical companies accounted for 18% in market share, comparable to 17.2% by the leading five multinational players.

• What will be the major growth indications and the accompanying growth drivers in the South Korean pharmaceutical industry over the next 5 years?
• Which were the leading players in the South Korean pharmaceutical market (both multinational and domestic) in 2008?
• How have recent launches from companies such as Dong-A, Sanofi-aventis, Daewoong Pharm, Hanmi and Pfizer performed in the market place?
• Which products will be the future growth drivers for the South Korean pharmaceutical market?
• Which therapeutic categories and indicationsare forecast to offer significant commercial opportunity over the period 2008–14?
• How is the competitive landscape of key therapeutic areas evolving in South Korea?

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004

Browse complete The Russian Pharmaceutical Market Outlook to 2014: Policy environment, market structure, competitive landscape, growth opportunities Report

Browse all Business Insights Market Research Reports

Russia’s well educated and low cost workforce is one of the main attraction for investors all over the world. According to recent statistics, Russia’s population (which is currently about 141m) is steadily declining at a rate of around 0.4%. Thus, the government is trying to remedy this through several immigration policies and federal programs such as stimulating birth rates and reducing mortality.
Russia has been one of the fastest growing emerging pharmaceutical markets in the world in recent years. The Russian healthcare industry is also experiencing robust growth which is primarily driven by several initiatives by the government such as improvement in primary care, efficient implementation of health insurance and an increase in healthcare financing.

Russia is an ideal branded generic market, as consumers are willing to pay higher prices for brands associated with quality. This is due to the fact that several domestic manufacturers operate plants that are not GMP (good manufacturing practice) compliant. As a result, foreign pharmaceutical companies have been effective at driving growth by promoting their brands over local products.
Russians are known to under spend on pharmaceutical products both in nominal and relative terms. In terms of public and out-of-pocket spending on pharmaceuticals, the Russian pharmaceutical market still lags behind the other emerging and developed countries. Out-of-pocket expenditure on pharmaceuticals accounts for the overwhelming majority of sales in Russia (which is much higher as compared to other OECD countries).

The Russian Pharmaceutical Market Outlook to 2014 provides comprehensive coverage of the Russian pharmaceutical market, market structure, pricing and regulation, and includes detailed epidemiological analyses of the common indications/risk factors. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share, sales forecast and competitive landscape for the major players in Russia. Furthermore, the report highlights the key market and R&D trends that may influence treatment sales, with a thorough analysis of the competitive dynamics of leading brands and indications in Russia. This will enable the reader to identify growth trends, key drug classes and leading players through to 2014.

Key features of this report

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004

Browse complete The Turkish Pharmaceutical Market Outlook to 2014: Policy environment, market structure, competitive landscape, growth opportunities Report

Browse all Business Insights Market Research Reports

Turkey, a ‘pharmerging’ market, has evolved to this status after a series of economic and healthcare reforms. The country was at the verge of financial collapse until 2001 with inflation running in near three digits. However, the economic reforms implemented by the country have turned it into a dynamic economy. The country’s pharmaceutical industry has been a frontrunner in these reforms. Turkey has a growing pharmaceutical sector with around 300 pharmaceutical companies selling up to 1.3bn units of products every year. Factors that have fuelled the growth of the pharmaceutical industry in the country include economic growth, high healthcare expenditures, a young workforce and a host of companies delivering drugs to the populace.

The reforms taken up by the country made the healthcare system more efficient, improving access for the population, besides bringing the system in sync with the standards of other EU nations. At the same time, the country’s growing economic consistency brought in foreign investment in the sector and bolstered consumer spending on pharmaceuticals. The healthcare reforms taken up by the country included implementation of a patent legislation in 1995, creation of a generics registration law in 1996 and establishment of a reference pricing system in 2004. However, the industry continues to have some problems still, such as a protracted product registration system and a reimbursement list that is deemed incomplete and biased.

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser’s URL address field. Remove the space if one exists.)

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004